Pharmaceutical Shares of Canadian drug developer Milestone Pharmaceuticals (Nasdaq: MIST) were down a massive 75% at $10.51 in pre-market trading today, after its announcement on Monday of disappointing top-line results from its Phase III, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of its investigational new drug, etripamil nasal spray. 24 March 2020